Histamine H2 receptor (H2R) blockade has been reported to be beneficial for patients with chronic heart failure (CHF), but the mechanisms involved are not entirely clear. In the present study, we assessed the influences of H2R disruption on left ventricular (LV) dysfunction and the mechanisms involved in mitochondrial dysfunction and calcineurin-mediated myocardial fibrosis. H2R-knockout mice and their wild-type littermates were subjected to transverse aortic constriction (TAC) or sham surgery. The influences of H2R activation or inactivation on mitochondrial function, apoptosis and fibrosis were evaluated in cultured neonatal rat cardiomyocytes and fibroblasts as well as in murine hearts. After 4 weeks, H2R-knockout mice had higher echocardiographic LV fractional shortening, a larger contractility index, a significantly lower LV end-diastolic pressure, and more importantly, markedly lower pulmonary congestion compared with the wild-type mice. Similar results were obtained in wild-type TAC mice treated with H2R blocker famotidine. Histological examinations showed a lower degree of cardiac fibrosis and apoptosis in H2R-knockout mice. H2R activation increased mitochondrial permeability and induced cell apoptosis in cultured cardiomyocytes, and also enhanced the protein expression of calcineurin, nuclear factor of activated T-cell and fibronectin in fibroblasts rather than in cardiomyocytes. These findings indicate that a lack of H2R generates resistance towards heart failure and the process is associated with the inhibition of cardiac fibrosis and apoptosis, adding to the rationale for using H2R blockers to treat patients with CHF.
Skip Nav Destination
Article navigation
Research Article|
June 17 2014
Disruption of histamine H2 receptor slows heart failure progression through reducing myocardial apoptosis and fibrosis
Zhi Zeng;
Zhi Zeng
*The State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China
Search for other works by this author on:
Liang Shen;
Liang Shen
*The State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China
Search for other works by this author on:
Xixian Li;
Xixian Li
*The State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China
Search for other works by this author on:
Tao Luo;
Tao Luo
*The State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China
Search for other works by this author on:
Xuan Wei;
Xuan Wei
*The State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China
Search for other works by this author on:
Jingwen Zhang;
Jingwen Zhang
*The State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China
Search for other works by this author on:
Shiping Cao;
Shiping Cao
*The State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China
Search for other works by this author on:
Xiaobo Huang;
Xiaobo Huang
*The State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China
Search for other works by this author on:
Yasushi Fukushima;
Yasushi Fukushima
†The Department of Internal Medicine, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo, Japan
Search for other works by this author on:
Jianping Bin;
Jianping Bin
*The State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China
Search for other works by this author on:
Masafumi Kitakaze;
Masafumi Kitakaze
*The State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China
‡Cardiovascular Division of the Department of Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan
Search for other works by this author on:
Dingli Xu;
Dingli Xu
*The State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China
Search for other works by this author on:
Yulin Liao
*The State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China
Correspondence: Dr Yulin Liao (email [email protected]).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
November 05 2013
Revision Received:
February 21 2014
Accepted:
March 21 2014
Accepted Manuscript online:
March 21 2014
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© The Authors Journal compilation © 2014 Biochemical Society
2014
Clin Sci (Lond) (2014) 127 (7): 435–448.
Article history
Received:
November 05 2013
Revision Received:
February 21 2014
Accepted:
March 21 2014
Accepted Manuscript online:
March 21 2014
Citation
Zhi Zeng, Liang Shen, Xixian Li, Tao Luo, Xuan Wei, Jingwen Zhang, Shiping Cao, Xiaobo Huang, Yasushi Fukushima, Jianping Bin, Masafumi Kitakaze, Dingli Xu, Yulin Liao; Disruption of histamine H2 receptor slows heart failure progression through reducing myocardial apoptosis and fibrosis. Clin Sci (Lond) 1 October 2014; 127 (7): 435–448. doi: https://doi.org/10.1042/CS20130716
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |